Version 1
: Received: 25 June 2024 / Approved: 26 June 2024 / Online: 26 June 2024 (13:16:38 CEST)
How to cite:
Lin, R. Y.; Kahramangil, D.; Ozer, M.; George, T. J.; Nassour, I.; Hughes, S. J.; Zarrinpar, A.; Sahin, I. Patient Outcomes in Resected Combined Hepatocellular Cholangiocarcinoma (cHCC-ICC) and Intrahepatic Cholangiocarcinoma: A Single Center Study. Preprints2024, 2024061868. https://doi.org/10.20944/preprints202406.1868.v1
Lin, R. Y.; Kahramangil, D.; Ozer, M.; George, T. J.; Nassour, I.; Hughes, S. J.; Zarrinpar, A.; Sahin, I. Patient Outcomes in Resected Combined Hepatocellular Cholangiocarcinoma (cHCC-ICC) and Intrahepatic Cholangiocarcinoma: A Single Center Study. Preprints 2024, 2024061868. https://doi.org/10.20944/preprints202406.1868.v1
Lin, R. Y.; Kahramangil, D.; Ozer, M.; George, T. J.; Nassour, I.; Hughes, S. J.; Zarrinpar, A.; Sahin, I. Patient Outcomes in Resected Combined Hepatocellular Cholangiocarcinoma (cHCC-ICC) and Intrahepatic Cholangiocarcinoma: A Single Center Study. Preprints2024, 2024061868. https://doi.org/10.20944/preprints202406.1868.v1
APA Style
Lin, R. Y., Kahramangil, D., Ozer, M., George, T. J., Nassour, I., Hughes, S. J., Zarrinpar, A., & Sahin, I. (2024). Patient Outcomes in Resected Combined Hepatocellular Cholangiocarcinoma (cHCC-ICC) and Intrahepatic Cholangiocarcinoma: A Single Center Study. Preprints. https://doi.org/10.20944/preprints202406.1868.v1
Chicago/Turabian Style
Lin, R. Y., Ali Zarrinpar and Ilyas Sahin. 2024 "Patient Outcomes in Resected Combined Hepatocellular Cholangiocarcinoma (cHCC-ICC) and Intrahepatic Cholangiocarcinoma: A Single Center Study" Preprints. https://doi.org/10.20944/preprints202406.1868.v1
Abstract
Combined hepatocellular cholangiocarcinoma (cHCC-ICC) is a rare malignancy that involves a combination of features of hepatocellular carcinoma and intrahepatic cholangiocarcinoma (ICC). cHCC-ICC is generally considered to exhibit a more aggressive clinical course compared to ICC; however, its risk factors and outcomes remain largely undefined. A single-center retrospective study of 82 patients diagnosed with ICC or cHCC-ICC from June 2011 and January 2023, all of whom underwent surgical resection. Our analysis included 70 patients with resected ICC and 12 with resected cHCC-ICC. The overall survival (OS) for the entire cohort was 21.6 months, with a recurrence-free survival (RFS) of 11.8 months. The cHCC-ICC group had significantly higher levels of AST and ALT (AST median 206 vs. 46; ALT median 165.5 vs. 48; p=0.012 and p=0.013, respectively), whereas the ICC group had higher alkaline phosphatase (median 66 vs. 104; p=0.03). CA 19-9 values (p=0.02) were higher in the ICC group, while AFP values were higher in the cHCC-ICC group (p=0.0004). The cHCC-ICC group had a significantly higher rate of recurrence (83% vs. 47%, p=0.028) with a significantly decreased RFS (4.7 months vs. 12.4 months; log-rank p=0.007). cHCC-ICC is a rare entity that needs to be further studied to improve patient outcomes. Our study showed that RFS is lower in the cHCC-ICC group as compared to ICC patients alone. Further studies are warranted and possibly suggest the need for more aggressive initial treatment strategies in patients diagnosed with cHCC-ICC.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
